

MOLECULAR CLONING AND SEQUENCING OF THE GENE ENCODING HUMAN ANGIOTENSIN II TYPE 1 RECEPTOR*

Hiroaki Furuta, Deng-Fu Guo, and Tadashi Inagami

*Department of Biochemistry, Vanderbilt University School of
Medicine, Nashville, TN 37232*

Received January 11, 1992

Summary: The gene of human angiotensin II type 1 (AT₁) receptor was isolated from a lymphocyte genomic library. The coding region of the human AT₁ receptor gene was contained in a single exon coding segment of the gene indicating an intronless structure of the coding region. The amino acid sequence of human AT₁ receptor deduced from its base sequence has 359 amino acids and showed a high degree of sequence identity to bovine and rat AT₁ receptor sequences. Amino acid substitutions specific to the human AT₁ receptor were mostly confined to the carboxy terminal half of the molecule. The seven-transmembrane domains are well-conserved in those sequences. © 1992 Academic Press, Inc.

Angiotensin II plays an important role in the homeostasis of blood pressure, fluid volume, electrolyte balance and cardiovascular hypertrophy through its action on specific receptors in its peripheral and central target tissues (1). Reflecting the versatility of the biological effects mediated by angiotensin II, its receptors have been detected in a wide variety of tissues: the vascular wall, adrenal, liver, kidney, lung, brain, and pituitary (2). Recently, Sasaki et al.(3) and Murphy et al.(4) reported the expression cloning and sequence analyses of bovine adrenal and rat aortic angiotensin II type 1 (AT₁) receptors, respectively. However, the structure of human AT₁ receptor and its gene remained unresolved. In this paper, we describe cloning of the human AT₁ receptor gene and its amino acid sequence deduced from the nucleotide sequence. Interestingly, the entire coding region was contained in a single exon.

*Sequence data from this article have been deposited with the EMBL/GenBank
Data Libraries under Accession No. Z11162.

Materials and Methods

Materials. Radiolabeled nucleotides [α - ^{32}P] dCTP (110TBq/mmol) were obtained from New England Nuclear (Boston, MA). Oligonucleotide primers were synthesized in a MilliGen/Biosearch Cyclone Plus DNA synthesizer. Dideoxy sequencing kits were from United States Biochemicals (Cleveland, OH).

Screening of genomic library. A human lymphocyte genomic library in lambda dash was obtained from Stratagene (La Jolla, CA). A total of 1.2×10^6 lambda phage plaques were screened on nylon membranes (Hybond-N, Amersham). Hybridization was performed at 42°C in a 6×SSC solution containing 2.5×Denhardt's, 30% formamide, 1% SDS with a labeled probe from rat SacI-KpnI DNA fragment for the AT₁ receptor (4,5). The membranes were washed twice with 2×SSC at room temperature for 5 min, then soaked twice at 55°C in 2×SSC containing 1% SDS and then exposed to radiographic film at -70°C with an intensifying screen. Positive clone was subcloned into Bluescript KS(+) plasmids.

Nucleotide sequencing. The nucleotide sequences of DNAs were determined by the dideoxy chain-termination method (6). Commercially available primers corresponding to plasmid sequences (T3 and T7) and synthetic oligonucleotide primers were used. Analysis of DNA data was performed by the DNA strider 1.0 program.

Results and Discussion

Out of approximately 1.2×10^6 recombinant phage five positive clones were selected by plaque hybridization of a genomic library. One clone contained a 6.1 kb *Bam* H1-fragment which were found to contain the complete reading frame of the human AT₁ receptor plus approximately 3.6 and 1.4 kb of 5'-and 3'-flanking regions, respectively (Fig. 1). The nucleotide sequence of the human AT₁ receptor gene and the corresponding amino acid sequence are shown in Fig. 2. The open reading frame consisting of 1,080 bp contained an initiation codon ATG and a termination codon TGA, and encoded 359 amino acids which accounted for a molecular mass of 41,066 daltons. The ATG sequence designated as the translational initiation codon agreed with Kozak's consensus sequence (7): C in nucleotide position -4, A in -3, and A in +4. Beyond the stop codon, two




Figure 1. Restriction map of human AT₁ receptor gene. A partial restriction map of the 6.1-kb *Bam* HI fragment containing human AT₁ receptor gene is shown. The *black bar* represents the human AT₁ receptor open reading frame.

putative polyadenylation signals (AATAAA) were located in the 3'-noncoding region, at +1947 and +2154, respectively. Six ATTTA nucleotide sequences (Fig. 2) are seen in the 3'-flanking regions which are considered as a motif common to transiently expressed labile mRNAs (8). Those sequences might cause the instability of the mRNA of human AT₁ receptor for posttranscriptional regulation. An exon-intron junction site was identified at the nucleotide position between -47 and -48 upstream of the initiation codon, and a poly(A) tail was located starting at +1968 in comparison with the base sequence of an AT₁ cDNA cloned from human liver (unpublished result from this laboratory). These results indicate that the human AT₁ receptor gene has an exon in which a complete uninterrupted open reading frame for the entire receptor is contained. The amino acid sequence of the human AT₁ receptor was 95.3 % identical to the bovine adrenal AT₁ receptor sequence (3) (see Fig. 3A) and 94.7 % to the rat (renal or vascular smooth muscle cell) AT₁ receptor sequence (4,5) all having uniformly 359 amino acid residues. At the base sequence level the human and bovine sequences showed 91.0% identity.

Hydropathy analysis (Fig. 3B) and comparison with bovine (3) and rat (4,5) AT₁ receptor sequences permitted assignment of seven putative transmembrane domains I-VII. One potential N-glycosylation site (Asn-X-Ser/Thr) is located in the N-terminal extracellular domain and two in the second extracellular loop. Each of the four extracellular domain contained one cysteine residue which would form two disulfide bonds essential for ligand binding. Positions of all of these amino acid residues are well conserved in rat and bovine AT₁ receptors. The amino terminal extracellular domain, the third intracellular loop and carboxy terminal cytoplasmic segment contain distinctly high hydrophilic sequences indicating their functions in the extra membrane space.


TTAATGATAAAATGAATGGTCTGCTTACCTCAGGAAAACTTCAAGTCTTTCTGAAAACTAATTT -396
 AATTCAGTAGTATTTTCTAAGATTTAGGTTATGTTTTTAATCAATTTGGAAACCAAGATTACTTATAGAAAAAAGGA -317
 AAAGGACCTAGATAGGTTTATTCACATAGAAATCCCAATTTTCACTTCTCTGGATGATACCATTTTCTACAAAAGCAATTA -238
 TGTTCATAAAATTAAGTGTGCTTCTTAGGCTTTATCAGTTCACAGTGTTCCTTAAGAAATATGATCCAGTATTTTTT -159
 CCTAAGACTAAAGTTGAGTTACTACGTTTATGACTGAGAAATGAATGTTTGTAGTTTGTGTTTACATAAGAATTT -80
 TTTCTTTACCATTTTATTTTATTTTCCCCAGGTGATTGTATAGTGTTCGAACAAATTCGACCCAGGTGATCAA -1

ATG ATT CTC AAC TCT TCT ACT GAA GAT GGT ATT AAA AGA ATC CAA GAT GAT TGT CCC AAA 60
Met Ile Leu Asn Ser Ser Thr Glu Asp Gly Ile Lys Arg Ile Gln Asp Asp Cys Pro Lys 20
 GCT GGA AGG CAT AAT TAC ATA TTT GTC ATG ATT CCT ACT TTA TAC AGT ATC ATC TTT GTG 120
Ala Gly Arg His Asn Tyr Ile Phe Val Met Ile Pro Thr Leu Tyr Ser Ile Ile Phe Val 40
 GTG GGA ATA TTT GGA AAC AGC TTG GTG ATA GTC ATT TAC TTT TAT ATG AAG CTG AAG 180
Val Gly Ile Phe Gly Asn Ser Leu Val Val Ile Val Ile Tyr Phe Tyr Met Lys Leu Lys 60
 ACT GTG GCC AGT GTT TTT CTT TTG AAT TTA GCA CTG GCT GAC TTA TGC TTT TTA CTG ACT 240
Thr Val Ala Ser Val Phe Leu Leu Asn Leu Ala Leu Ala Asp Leu Cys Phe Leu Leu Thr 80
 TTG CCA CTA TGG GCT GTC TAC ACA GCT ATG GAA TAC CGC TGG CCC TTT GGC AAT TAC CTA 300
Leu Pro Leu Trp Ala Val Tyr Thr Ala Met Glu Tyr Arg Trp Pro Phe Gly Asn Tyr Leu 100
 TGT AAG ATT GCT TCA GCC AGC GTC AGT TTC AAC CTG TAC GCT AGT GTG TTT CTA CTC ACG 360
Cys Lys Ile Ala Ser Ala Ser Val Ser Phe Asn Leu Tyr Ala Ser Val Phe Leu Leu Thr 120
 TGT CTC AGC ATT GAT CGA TAC CTG GCT ATT GTT CAC CCA ATG AAG TCC CGC CTT CGA CGC 420
Cys Leu Ser Ile Asp Arg Tyr Leu Ala Ile Val His Pro Met Lys Ser Arg Leu Arg Arg 140
 ACA ATG CTT GTA GCC AAA GTC ACC TGC ATC ATC ATT TGG CTG CTC GCA GGC TTG GGC AGT 480
Thr Met Leu Val Ala Lys Val Thr Cys Ile Ile Ile Trp Leu Leu Ala Gly Leu Ala Ser 160
 TTG CCA GCT ATA ATC CAT CGA AAT GTA TTT TTC ATT GAG AAC ACC AAT ATT ACA GTT TGT 540
Leu Pro Ala Ile Ile His Arg Asn Val Phe Phe Ile Glu Asn Thr Asn Ile Thr Val Cys 180
 GCT TTC CAT TAT GAG TCC CAA AAT TCA ACC CTT CCG ATA GGG CTG GGC CTG ACC AAA AAT 600
Ala Phe His Tyr Glu Ser Gln Asn Ser Thr Leu Pro Ile Gly Leu Gly Leu Thr Lys Asn 200
 ATA CTG GGT TTC CTG TTT CTT TTT CTG ATT CTT ACA AGT TAT ACT CTT ATT TGG AAG 660
Ile Leu Gly Phe Leu Phe Pro Phe Leu Ile Ile Leu Thr Ser Tyr Thr Leu Ile Trp Lys 220
 GCC CTA AAG AAG GCT TAT GAA ATT CAG AAG AAC AAA CCA AGA AAT GAT GAT ATT TTT AAG 720
Ala Leu Lys Lys Ala Tyr Glu Ile Gln Lys Asn Lys Pro Arg Asn Asp Asn Ile Phe Lys 240
 ATA ATT ATG GCA ATT GTG CTT TTC TTT TCC TGG ATT CCC CAC CAA ATA TTC ACT 780
Ile Ile Met Ala Ile Val Leu Phe Phe Phe Phe Ser Trp Ile Pro His Gln Ile Phe Thr 260
 TTT CTG GAT GTA TTG ATT CAA CTA GGC ATC ATA CGT GAC TGT AGA ATT GCA GAT ATT GTG 840
Phe Leu Asp Val Leu Ile Gln Leu Gly Ile Ile Arg Asp Cys Arg Ile Ala Asp Ile Val 280
 GAC ACG GCC ATG CCT ATC ACC ATT TGT ATA GCT TAT TTT AAC AAT TGC CTG AAT CCT CTT 900
Asp Thr Ala Met Pro Ile Thr Ile Cys Ile Ala Tyr Phe Asn Asn Cys Leu Asn Pro Leu 300
 TTT TAT GGC TTT CTG GGG AAA AAA TTT AAA AGA TAT TTT CTC CAG CTT CTA AAA TAT ATT 960
Phe Tyr Gly Phe Leu Gly Lys Lys Phe Lys Arg Tyr Phe Leu Gln Leu Leu Lys Tyr Ile 320
 CCC CCA AAA GCC AAA TCC CAC TCA AAC CTT TCA ACA AAA ATG AGC ACG CTT TCC TAC CGC 1020
Pro Pro Lys Ala Lys Ser His Ser Asn Leu Ser Thr Lys Met Ser Thr Leu Ser Tyr Arg 340
 CCC TCA GAT AAT GTA AGC TCA TCC ACC AAG AAG CCT GCA CCA TGT TTT GAG GTT GAG TGA 1080
Pro Ser Asp Asn Val Ser Ser Ser Thr Lys Lys Pro Ala Pro Cys Phe Glu Val Glu END 359

CATGTTTCCAAACCTGTCCATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCACTACCAA 1159
 ATGAGCATTAGCTACTTTTTCAGAATTGAAGGAGAAAAATGCATTATGTGGACTGAACCGACTTTTCTAAAGCTCTGAACA 1238
 AAAGCTTTTCTTCTTTTTCCTTTTGAACAAGACAAAGCAAGCCACATTTTGCATTAGACAGATGACGGCTGCTCGAAGAACA 1317
 ATGTCAGAAACTCGATGAATGTGTGATTGAGAAATTTTACTGACAGAAATGCAATCTCCCTAGCCTGCTTTTGTCCCT 1396
 GTTATTTTTTATTTCCACATAAAGGTTTATTAATATATTAATCGTTAGAGGAGCAACAGGAGATGAGAGTTCCAGAT 1475
 TGTTCGTCCAGTTTCCAAAGGCGAGTAAAGTTTTCGTGCGGTTTTCAGCTATTAGCAACTGCTGCTACACTTGCACC 1554
 TGGTACTGCACATTTTGTACAAAGATATGCTAAGCAGTAGTCGTCGAAGTTGCAGATCTTTTGTGAAATTCACCTGTG 1633
 TCTTATAGGTTTACACTGCCAAAACAATGCCCGTAAGATGGCTTATTGTATAATGGTGTTACTAAAGTCACATATAAA 1712
 AGTTAAACTACTTGTAAAGGTGCTGCACTGGTCCCAAGTAGTAGTGCTTCCCTAGTATATTAGTTTATTTAATATCTG 1791
 AGAAGTGATATAGTTTGTGGTAAACAGATTATATATCATCAAGTATGCCTTCTGTTTAAAAAAGATATATATCTACAC 1870
 ATATATATATATGATATATCTATATCTCTAAAGTCTGTAAATGATTAAAAATCGGCAAGTTATATTTACTTTAAAAAT 1949
 AAAATAATTTTATTGCAATGTTTATTTACTTCACTTAAAAATAGATGCTAATTTTAAAAATAAGACTACCTTGAA 2028
 TGAGTATGAATATATTTTATTTAATTTTGTACAACTGATAGTTTAACTATTTGGTTATAGATTTTATCTCTGAC 2107
 ATTGAAAAGTTAAAGAAAAACATTTTGTCTACTGCATGTCATGGAATAAACACATCGTTT

Figure 2. Nucleotide sequence and deduced amino acid sequence of a human AT₁ receptor gene. A stop codon is indicated as *END*. Two potential polyadenylation signals (AATAAA) are *underlined*. The nucleotide motifs corresponding to AUUUA, a putative mRNA destabilization signal (8) are enclosed within *boxes*. Both an exon-intron junction site and poly(A) tail start site in a cDNA encoding human AT₁ receptor are indicated with *asterisks*.

A



B




Figure 3. The alignment of the predicted protein sequence of the AT₁ receptor (A) and hydropathy analysis (B). A: Comparison of the primary structure of the human and bovine AT₁ receptor. Identical amino acids are shown by *asterisks* in the bovine sequence and non-identical residues are enclosed in *boxes*. The seven putative transmembrane domains are indicated above the amino acid sequences. The potential N-glycosylation sites are marked by *triangles*. B: Kyte-Doolittle (9) hydropathy analysis of the amino acid sequence of the human AT₁ receptor. The putative seven transmembrane domains are indicated with *black bars*.

Besides the similarity with bovine and rat AT₁ receptor structure, the present results uncovered that several specific substitutions are localized predominantly in the carboxy terminal half of the sequence.

Elucidation of the structural details of human AT₁ receptor will be very useful for the design of selective receptor antagonists for therapeutic purposes and identification of genetic disorders of the receptor in humans.

Acknowledgments

We thank Drs Marion L. Dodson and Makoto Yoshida for their aid on the computer analysis of sequences, Tim Atkinson for synthesizing oligonucleotides for sequencing, and Tina Stack for secretarial assistance. This work was supported by Research Grants HL14192 and HL 35323 from the National Institutes of Health of U.S.A.

References

1. Peach, M. J. (1977) *Physiol. Rev.*, 57, 313-370
2. Millan M. A., Carvallo P., Izumi S., Zemel S., Catt K. J., and Aguilera, G. (1989) *Science* 244, 1340-1342
3. Sasaki, K., Yamano, Y., Bardhan, S., Iwai, N., Murray, J. J., Hasegawa, M., Matsuda, Y. and Inagami, T. (1991) *Nature*, 351, 230-233
4. Murphy, T. J., Alexander, R. W., Griendling, K. K., Runge, M. S. and Bernstein, K. E. (1991) *Nature*, 351, 233-236
5. Iwai, N., Yamano, Y., Chaki, S., Konishi, F., Bardhan, S., Tibbetts, C., Sasaki, K., Hasegawa, M., Matsuda, Y. and Inagami, T. (1991) *Biochem. Biophys. Res. Commun.*, 177, 299-304
6. Sanger, F., Nicklen, S. and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. USA*, 74, 5463-5467
7. Kozak, M. (1984) *Nucleic Acids Res.*, 12, 857-872
8. Shaw, G., and Kamen, R. (1986) *Cell*, 46, 659-667
9. Kyte, J., and Doolittle, R. F. (1982) *J. Mol. Biol.* 157, 105-132